Navigation Links
BioMotiv Secures $46 Million in Funding

CLEVELAND, Aug. 5, 2013 /PRNewswire-USNewswire/ -- BioMotiv, a drug development accelerator based in Cleveland, Ohio, today announced that it has increased its total capital from investors to $46 million, adding Nationwide Mutual Insurance Company and several individual investors to its founding investors, University Hospitals of Cleveland and the Harrington Family.  Nationwide Mutual Insurance Company also will appoint a representative to serve on the Board of Managers of BioMotiv. 


"BioMotiv is a new business model for accelerating breakthrough discoveries into medicines, aligning capital and collaborations to develop a portfolio of therapeutics," said Baiju R. Shah, Chief Executive Officer of BioMotiv.  "This support from local institutions and investors provides the company a strong foundation on which to build nationally."

Launched last year, BioMotiv has established its organization and operations and attracted a world-renowned advisory board that includes several former heads of global pharmaceutical research and development organizations to manage a portfolio of promising drug technologies.  The company is affiliated with The Harrington Project for Discovery and Development, a $250 million national initiative initiated by University Hospitals.

"We license early-stage technologies and then develop them with the oversight of our experienced team and network of partners," said Shah.  BioMotiv has begun work on several promising technologies sourced from research institutions and industry sources.

BioMotiv continues to seek additional early-stage therapeutic technologies that are at the pre-clinical or early-clinical stage of development. 

About The Harrington Project

The Harrington Project for Discovery and Development is a $250 million national initiative to support the discovery and development of breakthrough discoveries by physician-scientists.  The Harrington Project, centered at University Hospitals Case Medical Center, is a new and powerful national model that addresses a set of challenges in advancing medicine through its innovative approach.  It includes the Harrington Discovery Institute and BioMotiv. The project, powered by a generous gift and investment from the Harrington family, successful entrepreneurs and recognized philanthropists in Cleveland, provides a comprehensive model to advance discoveries into development and to create novel therapies for patient care.

For more information about the Harrington Discovery Institute, go to:

For more information about BioMotiv, go to:

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMotiv Secures $21 million in Initial Funding
2. BioMotiv Names New Chief Executive Officer
3. Stark Medical Secures GSA Schedule Contract, Looks to Supply VA
4. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
5. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
6. SecureState Identifies Top 5 Vulnerabilities Facing Hospitals and Medical Device Manufactures
7. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
8. Chronic Kidney Disease: Reducing Risks of Progression-- Prismic Pharmaceuticals Secures Exclusive Licensing Rights
9. United Spinal Secures Victory in Protecting Access to Complex Rehab Technology in Washington State
10. Alimera Sciences Secures $20 Million Debt Facility
11. Henry Schein Secures $300 Million Of Committed Financing
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
(Date:11/25/2015)... Asia -based venture ... and the New Investors will make a direct equity ... private placement. The financing will help IOPtima to continue ... in the treatment of glaucoma, as well as to ... system with the U.S. Food and Drug Administration, commencing ...
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ... and regulatory/legal strategies all play a key ... says GBI Research . --> ... a key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug ... need to integrate dose form selection in early phase drug development. The first ... supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is ... 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an ... every day excited to rebuild lives and it’s an honor to have served all ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
Breaking Medicine News(10 mins):